PetMed Express, Inc. filings document the regulatory record for a Florida public company operating the PetMeds and PetCareRx pet pharmacy businesses. Annual and current reports disclose operating results, non-GAAP reconciliations, intangible-asset impairment matters involving the PCRX trade name, and the financial reporting issues reflected in Forms 12b-25 and Nasdaq continued-listing notices.
Other filings cover governance and capital-structure matters, including annual meeting voting results, director elections, executive compensation advisory votes, audit committee composition, amendments to the shareholder rights agreement, and modifications to security holder rights. The record also includes Form 8-K disclosures for material agreements, board appointments, results releases, and listing compliance communications.
PetMed Express, Inc. filed a comprehensive Annual Report and restated prior periods after an Audit Committee review found income statement classification errors. The company had recorded vendor-funded promotional reimbursements in revenue; under U.S. GAAP these amounts should reduce cost of sales and/or advertising. The corrections revise revenue, cost of sales, and advertising line items but have no impact on net income, cash flows, balance sheet, or equity.
The Audit Committee concluded earlier financial statements should no longer be relied upon, and the independent auditor issued an adverse opinion on internal control over financial reporting. PetMed highlights remediation efforts in Controls and Procedures. Operationally, AutoShip and membership accounted for approximately 56.1% of sales in the quarter ended March 31, 2025, average order value was about $97 in fiscal 2025, and approximately 351,000 new customers were added in fiscal 2025. Shares outstanding were 21,015,559 as of September 30, 2025.
PetMed Express, Inc. reports a $1.2 million non-cash impairment of its PCRX trade name, to be recorded in the quarter ended March 31, 2025, after reduced actual and forecasted revenues indicated the asset’s fair value fell below its book value. The company warns that a sustained decline in its stock price could trigger a quantitative goodwill test and potentially a material additional non-cash impairment in the first fiscal quarter of 2026.
The Audit Committee determined that prior financial statements for fiscal years ended March 31, 2024 and 2023, and certain 2024–2025 quarters, should no longer be relied upon due to income statement classification errors for vendor incentives. Restatement will reclassify amounts such as approximately $6,969,000 and $9,010,000 from net sales to cost of sales and/or advertising, but is not expected to change net income, earnings per share, cash flows or liquidity. An internal investigation into whistleblower reports found revenue timing issues on AutoShip orders, a coupon promotion misclassified in cost of goods sold, control and culture concerns, and policy violations, leading to the resignations of the former CEO, CFO and Audit Committee Chair and the expectation of material weaknesses in internal control. The company aims to file its delayed 2025 Form 10-K by mid-October 2025.
Douglas Krulik, Chief Accounting Officer of PetMed Express, Inc. (PETS), reported a non‑derivative equity grant on 09/09/2025. The filing shows a restricted stock award of 10,000 shares granted at a $0 purchase price under the companys 2024 Omnibus Incentive Plan. After the grant Mr. Krulik beneficially owns 50,000 shares. The award is scheduled to vest in full on the six‑month anniversary of the grant date provided he remains employed or in service, and the award also vests in full if the company terminates his service prior to full vesting unless the termination is for Cause. The Form 4 is signed by Mr. Krulik on 09/11/2025.
Douglas Krulik, Chief Accounting Officer of PetMed Express, Inc. (PETS), was granted 40,000 restricted stock units (RSUs) on 09/27/2024. The RSUs were issued under the Company’s 2024 Inducement Incentive Plan and vest in three equal annual installments — one-third on each of the first, second and third anniversaries of 09/27/2024 — subject to continued employment except as otherwise provided in the RSU agreement. Each RSU represents the right to receive one share of common stock upon vesting. Following the grant, Mr. Krulik is reported to beneficially own 40,000 shares directly. The Form 4 was signed by Mr. Krulik on 09/11/2025.
Douglas Krulik, identified as Chief Accounting Officer and a director of PetMed Express, Inc. (ticker: PETS), filed an Initial Statement of Beneficial Ownership (Form 3) reporting the event date of 08/19/2024. The filing states that no securities are beneficially owned by the reporting person. The form indicates it was filed by one reporting person and includes a manual signature dated 09/11/2025. The document provides the reporting person’s business address in Delray Beach, Florida, and confirms compliance with Section 16 reporting requirements through this submission.
PetMed Express, Inc. reported receiving a Nasdaq notice on August 20, 2025 stating it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not yet filed its Annual Report on Form 10-K for the year ended March 31, 2025 and its Quarterly Report on Form 10-Q for the period ended June 30, 2025.
The company has until September 1, 2025 to submit a plan to regain compliance and, if Nasdaq accepts the plan, may be given up to December 29, 2025 to become current in its filings. The notice does not immediately affect the listing of PetMed’s common stock on Nasdaq.
PetMed states it is working diligently to complete and file the delayed reports as promptly as possible so it can regain compliance with Nasdaq’s listing standards.
PetMed Express insider purchase reported. Silvercape Investments Ltd filed a Form 4 showing it acquired 101,000 shares of PETS at $3.17 on 08/13/2025, increasing its direct beneficial ownership to 2,579,696 shares. The filing lists the reporting relationship as Director, shows transaction code P (purchase), and is signed by Peter Kennedy on 08/14/2025.
PetMed Express reported that on August 11, 2025 its Chief Executive Officer and President, Sandra Campos, and its Chief Financial Officer and Treasurer, Robyn D’Elia, resigned effective immediately. Under separation agreements the Company will continue each officer’s annual base salary for 13 months ($550,000 for Ms. Campos; $425,000 for Ms. D’Elia), reimburse COBRA premiums for 18 months, and accelerate pro‑rata vesting of certain restricted stock units while other equity awards will be forfeited. The Board reduced its size from six to five and appointed Leslie C.G. Campbell as Interim CEO and President and Doug Krulik as Interim Principal Financial Officer (while he continues as Chief Accounting Officer). The filing discloses an ongoing Audit Committee investigation into autoship revenue recognition, a $50 coupon promotion, and the company’s control environment; a press release was furnished as Exhibit 99.1.
PetMed Express, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 because the company's Audit Committee investigation described in a Current Report filed July 1, 2025 remains incomplete.
The company says completion of that investigation is required to finish and file its Annual Report for the fiscal year ended March 31, 2025, which must be filed before the 10-Q. PetMed indicates a significant change in results is anticipated but cannot reasonably estimate amounts at this time. Contact: Robert Lawsky, General Counsel.